ESRRG suppress cell proliferation in prostate cancer cells (40) and the estrogen receptor beta agonist diarylpropionitrile (DPN) exhibit a pro-apoptotic and anti-proliferative effect on MB (41). Here, ESRRG is linked to prostate carcinoma.